kallikrein related peptidase 5Genealiases: KLK-L2 · KLKL2 · SCTE
Q-omics provides the consensus-scored KLK5 profile across patient tissues and cancer cell-line models. KLK5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, KLK5 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, KLK5 RNA expression shows 10,517 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRC, and TGCT as cancer lineages where KLK5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK5 survival associations across molecular data types. KLK5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK5 RNA expression–survival associations across cancer types. High KLK5 expression shows unfavorable associations in COAD, BLCA, SKCM, SCLC and UCEC, but favorable associations in THCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for KLK5 RNA expression.
This table summarizes KLK5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KLK5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK5 shows lower tumor expression in KIRC, BRCA, KICH and KIRP and higher tumor expression in COAD and THCA. The KIRC box plot shows higher KLK5 RNA expression in normal versus tumor tissue (log2 FC = −1.067, t-test p < 0.001).
This table shows molecular features associated with KLK5 in patient tissues and cancer cell lines. In patient samples, KLK5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and OVARY.
